Clinical and Biological Characteristics of Hidradenitis Suppurativa

a study on Hidradenitis Suppurativa

Summary

Eligibility
for people ages 13 years and up (full criteria)
Healthy Volunteers
healthy people welcome
Location
at San Francisco, California
Dates
study started
estimated completion
Principal Investigator
by Haley B Naik, MD, MHSc, FAAD
Headshot of Haley B Naik
Haley B Naik

Description

Summary

Hidradenitis suppurativa (HS) is a common and debilitating skin disease that is poorly understood and understudied. As a result, little is known about disease prognosis and few effective treatments exist for this condition. This prospective observational cohort study aims to comprehensively characterize the clinical and biological features of HS. The results of this research will provide a basis for the development of an HS clinical classification system and identification of potential treatments for HS.

Keywords

Hidradenitis Suppurativa, Hidradenitis

Eligibility

For people ages 13 years and up

Hidradenitis Suppurativa Patients

Inclusion Criteria:

  1. Age 13 years or older
  2. Diagnosis of HS clinically-confirmed by a physician

Exclusion Criteria:

  1. Inability to give informed consent or have a parent/guardian who is able and willing to give informed consent.

Healthy Volunteer

Inclusion Criteria:

  1. No history of chronic skin conditions
  2. No recent history of antibiotic use

Exclusion Criteria:

  1. Inability to give informed consent or have a parent/guardian who is able and willing to give informed consent.

Location

  • UCSF accepting new patients
    San Francisco California 94115 United States

Lead Scientist at UCSF

  • Haley B Naik, MD, MHSc, FAAD
    Hidradenitis Suppurativa (HS) is a prevalent and debilitating disease predominating in women and minorities. Despite its prevalence and morbidity, the biology of HS is poorly understood, thus limiting the development of effective therapies.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, San Francisco
ID
NCT03967600
Study Type
Observational [Patient Registry]
Participants
Expecting 1000 study participants
Last Updated
Contact us about this trial